TEST:

VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody

MSI estimation using NGS is suitable as a quick screening tool. Since thresholds for MSI-H might differ enormously between entities, additional IHC testing is recommended at least in samples where VUS or pathogenic mutations are found in one of the mismatch repair genes. Downloaded from http://karger.com/ort/article-pdf/47/Suppl.

CLDN18.2+ expression is associated with early stage GACs, but with metastatic disease in E/GEJACs. CLDN18.2+ expression is not affected by preoperative treatment or HER2 status. These findings expand our recognition of subsets of patients who may benefit from targeted CLDN18.2 therapy.

The expression of PD-L1 was associated with high grade tumour, lymph nodal metastasis, LVI and nodal stage, hence propends for creating targeted therapy with ICI. dMMR, however was noted only in 2% of cases which showed high PDL1 expression.

The expression of PD-L1 was associated with high grade tumour, lymph nodal metastasis, LVI and nodal stage, hence propends for creating targeted therapy with ICI. dMMR, however was noted only in 2% of cases which showed high PDL1 expression.